clinical trial · NCT05271604
A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Head and Neck CancerSquamous Cell Carcinoma of Head and NeckRecurrent Squamous Cell Carcinoma of the Head and NeckMetastatic CancerMetastatic Squamous Cell Carcinoma of the Head and NeckOzuriftamab VedotinPembrolizumabEvalstotug (BA3071)Cetuximab
brief summary
This is a multi-center, open-label Phase 2 study designed to evaluate the efficacy and safety of BA3021 as monotherapy and combination therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
started
Dec 13, 2022
primary completion
Sep 22, 2025
completion
Sep 22, 2025
last updated
Sep 26, 2025
official title
A Phase 2 Open-Label Study of Ozuriftamab Vedotin (BA3021) in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol